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RNA binding proteins are key players in posttranscriptional regulation and have been implicated in neuro­
developmental and neuropsychiatric disorders. Here, we report a significant burden of heterozygous, likely 
gene­ disrupting variants in CSDE1 (encoding a highly constrained RNA binding protein) among patients with 
autism and related neurodevelopmental disabilities. Analysis of 17 patients identifies common phenotypes 
including autism, intellectual disability, language and motor delay, seizures, macrocephaly, and variable 
ocular abnormalities. HITS­CLIP revealed that Csde1­binding targets are enriched in autism­associated gene 
sets, especially FMRP targets, and in neuronal development and synaptic plasticity–related pathways. Csde1 
knockdown in primary mouse cortical neurons leads to an overgrowth of the neurites and abnormal dendritic 
spine morphology/synapse formation and impaired synaptic transmission, whereas mutant and knockdown 
experiments in Drosophila result in defects in synapse growth and synaptic transmission. Our study 
defines a new autism­related syndrome and highlights the functional role of CSDE1 in synapse development and 
synaptic transmission.
INTRODUCTION
Autism spectrum disorder (ASD) is a group of neurodevelopmental 
disorders (NDDs) with considerable genetic and clinical heteroge-
neity (1). The core behavioral abnormalities are characterized by 
impairments in social communication and interaction, restricted 
interests, and repetitive behaviors, as defined in the Diagnostic and 
Statistical Manual of Mental Disorders, Fifth Edition (DSM-5) 
(2). In addition to the core symptoms, language delay and intellec-
tual disability (ID) are two of the most common co-occurring 
conditions. Genetic studies have implicated hundreds of suscepti-
bility genes (https://gene.sfari.org/) (3), and de novo variants in 
more than 100 genes confer increased risk for ASD (4–6). Even so, 
these genes account for only a small fraction of patients (7), suggest-
ing that a large number of genes with extremely rare variants await 
discovery as study sample sizes increase (5).
Enrichment and pathway analyses have shown that ASD risk 
genes are frequently associated with transcriptional regulation, 
especially targets of RNA binding proteins (RBPs) (5, 6, 8). RBPs 
mainly function in posttranscriptional gene regulation, which is 
essential to sustain cellular metabolism, coordinating maturation, 
transport, stability, and degradation of all classes of RNAs (9). In 
particular, two RBPs have been linked to ASD and NDDs, namely, 
RBFOX1 (10) and FMRP (11) encoded by FMR1, the fragile X syn-
drome (FXS) gene. Identification of these genes and their RNA 
binding targets has been important in the identification of ASD 
disease networks and potential therapeutic interventions (10, 11).
CSDE1, also known as UNR, encodes a highly conserved RBP 
containing five cold-shock domains and has been implicated in 
both neuronal migration and differentiation (12, 13). Our previous 
genome-wide association study suggested CSDE1 as a potential 
ASD risk gene (14). Using a targeted sequencing approach and with 
collaboration of multiple international centers, we found and report 
on the phenotypes of 18 patients with likely gene-disrupting (LGD) 
variants in CSDE1, identifying a new ASD-related syndrome. 
High-throughput sequencing of RNA isolated by cross-linking 
immunoprecipitation (HITS-CLIP) analyses show that Csde1- 
binding targets are significantly enriched in ASD-related genes and 
significantly overlap FMRP and RBFOX targets. In vitro and in vivo 
functional analyses highlight the important role of Csde1 in neuronal 
development and synaptic transmission.
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RESULTS
CSDE1 disruptive variants associate with ASD  
and related NDDs
We initially targeted the coding region of CSDE1 using a modified 
single-molecule molecular inversion probe (smMIP) approach 
(Materials and Methods) among 4045 ASD probands from the 
Autism Clinical and Genetic Resources in China (ACGC) cohort 
and identified three de novo LGD variants (two nonsense and one 
canonical splice site) from two simplex quad families and one trio 
family (CC1.p1, CC2.p1, CC3.p1; Table 1 and Fig. 1). We applied 
the chimpanzee-human divergence model (CH model) (15) to 
calculate the excess probability of de novo LGD variants within 
CSDE1 (Materials and Methods) and observed that the probability 
of detecting three or more de novo LGD variants within CSDE1 in 
the ACGC cohort is significant (P = 1.98 × 10−7, binomial test) 
even after genome-wide multiple testing correction (Padj = 0.004, 
binomial test, Bonferroni correction).
On the basis of this observation, we targeted CSDE1 for sequenc-
ing in a larger international cohort of patients in the Autism 
Spectrum/ID network (Materials and Methods). We identified and 
validated five additional LGD variants (AA.p1, CC4.p1, SS2.p1, 
TA.p1, and TI.p1; Table 1 and Fig. 1). In this cohort, four of the five 
variants were inherited and only one was a de novo variant. Un-
fortunately, no detailed clinical follow-up or neuropsychiatric 
assessment could be performed on the carrier parents in this 
subset. Last, by leveraging the web-based platform GeneMatcher 
(16) and personal communications with our collaborators, we 
collected 10 additional patients (NN1.p1, NN2.p1, PU1.p1, PU2.p1, 
BU1.p1, BU2.p1, SS1.p1, SU1.p1, SU2.p1, and TU.p1; Table 1 and 
Fig. 1) with CSDE1 LGD variants and neurodevelopmental pheno-
types (table S1). Four are de novo, three are inherited, and, in two, 
the father’s DNA was not available. Each of the carrier parents and 
sibling either exhibited mild neurodevelopmental phenotypes or 
presented with substantial family history of ASD or developmental 
disability (DD) (Fig. 1B). The carrier father in family PU2, for 
example, was previously diagnosed with global developmental 
delay, and the sibling who also carries this variant has a history of 
ASD, seizures, and anxiety. The carrier father in family BU2 pre-
sented with a history of language and motor delays, suspected ID, 
and macrocephaly—features also observed in the proband. The 
carrier father in family SU1 has a specific learning disability. Family 
PU1 has substantial maternal family history of epilepsy and anxiety 
disorder (extended family members not tested) (Fig. 1B). In addi-
tion to LGD variants, we also collected three patients with de novo 
missense variants (table S1) through this effort.
In total, we identified 18 families with CSDE1 LGD variants, 
including eight de novo, eight inherited, and two with undeter-
mined inheritance (Table 1 and Fig. 1). We observed one CpG- 
mediated recurrent site of variant (p.R123*) identified in three 
independent families: two de novo and one inherited. On the basis of 
all patient data, we estimated genome-wide significance of the ge-
netic findings. First, we identified seven patients (NN1.p1, SS1.p1, 
TI.p1, BU1.p1, CC1.p1, CC2.p1, and CC3.p1; Table 1) with de novo 
LGD variants from cohorts, for a total of 19,745 individuals. These 
data suggest a significant excess of de novo LGD variants after 
genome-wide multiple testing correction (Padj = 3.6 × 10−9, binomial 
test, Bonferroni correction) (Materials and Methods). Second, 
CSDE1 is highly intolerant to variants, as predicted by the proba-
bility of loss-of-function intolerance score (pLI = 1.00) (17) and 
the residual variation intolerance score (%RVIS = 6.18) (18). 
No LGD variants are present in the 1000 Genomes Project or 
the Exome Sequencing Project; only one LGD variant was iden-
tified in 45,375 Exome Aggregation Consortium (ExAC) non- 
neuropsychiatric samples (19). We estimated the mutational burden 
of 15 CSDE1 LGD variants screened from cohorts with a total of 
28,655 probands versus 45,375 ExAC non-neuropsychiatric subset 
samples (Materials and Methods). By this metric, probands show a 
significant burden of LGD variants regardless of inheritance status 
[odds ratio (OR), 22.2; P = 1.6× 10−5, two-tailed Fisher’s exact test]. 
We note that the mean sequence cover age of CSDE1 exons is more 
than 40-fold (fig. S1), so this difference is unlikely the result of low 
sequence coverage in ExAC. These data strongly support the association 
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Table 1. Summary of CSDE1 LGD variants. Isoform, NM_001242891. BCM, Baylor College of Medicine; WES, whole-exome sequencing; gDNA, genomic DNA; 
cDNA, complementary DNA; SSC, Simons Simplex Collection. 
Patient ID Cohort Method Function Cohort size Variant in gDNA (hg19,chr1) Variant in cDNA Protein change Inheritance
PU2.p1 Providence WES Stopgain – g.115282407_115282407delG c.243_243delC p.S82Lfs*28 Paternal
BU2.p1 Bethesda WES Stopgain – g.115282401_115282402insT c.248_249insA p.Y83* Paternal
NN1.p1 Nijmegen WES Frameshift 2,418 g.115282363delA c.287_287delT p.F96Sfs*14 De novo
SU2.p1 San Francisco WES Stopgain – g.115280664G>A c.367C>T p.R123* De novo
SS1.p1 SSC WES Stopgain 2,508 g.115280664G>A c.367C>T p.R123* De novo
AA.p1 Adelaide Target Stopgain 10,745 g.115280664G>A c.367C>T p.R123* Maternal
TI.p1 Troina Target Frameshift 10,745 g.115275369_115275370TT c.1043_1044delAA p.K348Rfs*12 De novo
BU1.p1 Baltimore WGS Stopgain 29 g.115275305G>A c.1108C>T p.R370* De novo
CC1.p1 ACGC Target Stopgain 4,045 g.115275239C>A c.1174G>T p.E392* De novo
CC4.p1 Changsha Target Splicing 10,745 g.115273044C>T c.1330-1G>A – Paternal
PU1.p1 BCM WES Frameshift 8,910 g.115273009_115273010insT c.1363_1364insA p.R455Kfs*3 Maternal
CC2.p1 ACGC Target Frameshift 4,045 g.115269672_115269673insC c.1533_1534insG V512Gfs*23 De novo
CC3.p1 ACGC Target Splicing 4,045 g.115269008C>T c.1603-1G>A – De novo
TA.p1 TASC Target Stopgain 10,745 g.115268971G>A c.1639C>T p.Q547* Paternal
NN2.p1 Nijmegen WES Frameshift 2,418 g.115267916_115267917insC c.1816_1817insG p.D606Gfs*6 Not maternal
SU1.p1 BCM WES Splicing 8,910 g.115267840T>C c.1891+2A>G – Paternal
TU.p1 BCM WES Frameshift 8,910 g.115261250_115261250delC c.2471_2471delG p.G824Dfs*30 Not maternal
SS2.p1 Swedish Target Frameshift 10,745 g.115260816_115260819delTCTT c.2506_2509delAAGA p.K836Sfs*17 Maternal
p.R123*/++/+ p.E392*/+p.K348Rfs*12/+
+/++/++/++/+ +/++/+
c.1603-1G>A/+
+/++/+
+/+ +/+
BU2
+/+p.Y83*/+
PU2
p.S82Lfs*28/+
A De novo Inherited Unknown
B
V512Gfs*23/+
+/++/+
NM_001242891
+/+
p.F96Sfs*14/+
SU1
c.1891+2A>G/+
+/+c.1891+2A>G/+
PU1
p.R455Kfs*3/+
+/+ p.R455Kfs*3/+
p.Y83*/+
SS1 CC1TI CC3CC2NN BU1
+/+
SU2
+/+
p.R370*/+p.R123*/+
p.R123*
p.K348Rfs*12
p.E392*
p.V512Gfs*23
p.Q547*
p.R455Kfs*3
p.G824Dfs*30
p.S82Lfs*28
p.Y83*
p.F96Sfs*14
p.R370*
p.K836Sfs*17
NP_001229820.1 CSD domain
p.R123*
p.R123*
N C
+/++/+ +/+
5 3
c.1330-1G>A
c.1603-1G>A
c.1891+2A>G
TA
+/+p.Q547*+
CC4
c.1330-1G>A/+
+/+c.1330-1G>A/+
p.Q547*/+
SS2
+/+ p.K836Sfs*17/+
AA
p.R123*/+
+/+ p.R123*/+
p.K836Sfs*17/+
? ? ??
+/+
p.S82Lfs*28/+ p.S82Lfs*28/+
p.D606Gfs*6
Fig. 1. Spectrum of CSDE1 LGD variants and patient facial features. (A) Diagram of the canonical CSDE1 isoform (NM_001242891.1 and NP_001229820.1). The locations 
of LGD variants are indicated. (B) Pedigrees of eight families with de novo LGD variants (above) and eight families with transmitted LGD variants (below). Carrier parents 
or sibling in at least four families (PU2, BU2, SU1, and PU1) are affected or show substantial family history.
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of both inherited and de novo LGD variants in CSDE1 with ASD 
and related NDDs.
Disruption of CSDE1 defines a new ASD-related syndrome 
in early development
Through patient recontact and a review of the available clinical 
records, we assembled a phenotypic description for 17 probands 
ranging in age from 3 to 19 years old (average age of 8.5 years) 
(Table 2 and table S1). Only one of the probands was an adult. The 
most consistent phenotypes include ASD, ID, delayed speech, and 
delayed motor development (Table 2). Of the 15 individuals with 
ASD evaluation, 10 were formally diagnosed with ASD, whereas 1 
had clinical impression of ASD. Although ASD assessment was not 
attempted in the other two patients, autistic features including 
repetitive behavior were reported for one of them (Table 2). Of the 
16 individuals for whom cognitive ability was assessed, 14 had a 
diagnosis of mild-to-severe ID and the remaining 2 patients had 
cognitive performance in the below-average range of intellectual 
functioning. All 17 probands had delay in speech, and motor delay was 
observed in 15 of 17 individuals for whom information was available.
In addition, we noted several common comorbidities in probands 
with CSDE1 LGD variants (Table 2). Seven of 16 patients (44%) had 
recurrent seizures or epilepsy. Six of 14 patients (43%) reported in-
creased head circumference or macrocephaly. Seven of 14 patients 
(50%) presented with abnormalities on brain magnetic resonance 
imaging (MRI). Anxiety behavior (7 of 13, 54%) and parent-reported 
attention-deficit/hyperactivity disorder (ADHD) (9 of 13, 69%) were 
also highly associated. In addition to neurological and behavior prob-
lems, several common systemic problems were also observed. Variable 
ocular abnormalities were present in 7 of 13 patients (54%), including 
iris coloboma, hyperopia, and strabismus. Six of 15 patients (40%) 
had hand findings, including 4 with brachydactyly, 1 with fifth finger 
clinodactyly, and 1 with polydactyly. Six of 13 patients (46%) had 
hypotonia.
The only adult proband (AA.p1) identified in this study showed 
apparently substantial progress in the management of neurodevel-
opmental issues since childhood and now presented with good 
social skills and milder ID. Instead, the individual has substantial 
psychiatric difficulties described as mild depression as a teenager 
and a formal diagnosis of schizophrenia at the age of 18 years.
Csde1 RNA binding targets enriched in ASD-related gene sets
To identify the RNA targets of Csde1 in the nervous system, we per-
formed HITS-CLIP using mouse whole brain (Materials and Methods). 
We performed two independent experiments that showed a median 
correlation of R = 0.43 (fig. S2A). We applied two software programs, 
ABLife and Piranha, to call the binding peaks in each experiment 
(Materials and Methods). We found that Csde1 binds mRNA across 
the gene body, including the coding sequence, 3′ untranslated region, 
and intronic regions. Of the known targets of mammalian Csde1, 
we identified Csde1 and Pabpc1 mRNAs in both independent ex-
periments. We subsequently selected 26 NDD-associated genes 
identified in both experiments or by both calling programs for valida-
tion by RNA immunoprecipitation sequencing (RIP-seq). We vali-
dated 76.9% of these targets (table S2). Although invalidated genes 
do not necessarily imply false positive binding, we report a higher 
validation rate (14 of 16, 87.5%) in genes identified by both peak- 
calling programs from both experiments (table S2). Applying this cri-
terion yields 210 targets, of which 184 have human homologs (table S3).
Using this high-confidence gene set, we tested whether Csde1- 
binding targets are enriched in ASD-associated genes. We considered 
seven ASD-associated gene sets: (i) FMRP RNA binding targets (11), 
(ii) RBFOX (RBFOX1/2/3) RNA binding targets (10), (iii) RBFOX 
splicing targets (10), (iv) ASD-associated genes [Simons Foundation 
Autism Research Initiative (SFARI)], (v) DD-associated genes (20), 
(vi) genes encoding postsynaptic density proteins (21), and (vii) genes 
involved in the synaptome (21). We revealed that Csde1-binding 
targets are significantly enriched in all gene sets (Fig. 2A). We ob-
served a greater than threefold enrichment with ASD-associated 
(OR, 3.79; P = 5.47 × 10−10, two-tailed Fisher’s exact test) and 
DD-associated (OR, 3.66; P = 2.38 × 10−4, two-tailed Fisher’s exact 
test) genes (Fig. 2A). Unexpectedly, Csde1-binding targets most 
strongly overlap the targets of other ASD-related RBPs, FMRP (OR, 9.22; 
P = 2.18 × 10−32, two-tailed Fisher’s exact test) and RBFOX (OR, 5.36; 
P = 5.45 × 10−18, two-tailed Fisher’s exact test) (Fig. 2A). Among 
184 Csde1 targets, 80 (43.5%) are overlapped with either FMRP targets 
(n = 62) or RBFOX targets (n = 50) (Fig. 2B). Notably, among the 
36 SFARI genes that Csde1 binds, 29 (80.5%) are overlapped with 
either FMRP (n = 25) or RBFOX (n = 18) targets (Fig. 2C). Gene 
Ontology and Kyoto Encyclopedia of Genes and Genomes (KEGG) 
pathway analyses revealed that Csde1-binding targets associate with 
synapse development and plasticity and with neuronal development– 
related cell components and pathways (Fig. 2D and fig. S2B).
Disruption of Csde1 interferes with synapse  
development and synaptic transmission in mouse cortical 
pyramidal neurons
CSDE1 is widely expressed in different human tissues (22). To better 
understand the spatiotemporal expression pattern of CSDE1, we 
further investigated CSDE1 mRNA expression pattern using RNA 
sequencing data from the Human Brain Transcriptome database 
(http://hbatlas.org/) (23). CSDE1 mRNA is expressed in a variety of 
different areas of the brain, showing the highest level of expression 
during embryogenesis, decreasing slightly postnatally but maintaining 
a high level across the whole lifespan (fig. S3A). We also assessed 
protein expression patterns by Western blot using embryonic and 
early postnatal mouse brains. Similar to the human mRNA expression 
pattern, the Csde1 protein is highly expressed in the cortex and cerebel-
lum during the embryonic and postnatal stages of mouse development 
(fig. S3B).
We next investigated whether Csde1 is required for neuronal and 
synapse development. Because Csde1 is highly expressed in the cortex 
and most of the disease-associated CSDE1 variants are predicted or 
validated (fig. S4) to result in loss of function, we designed two distinct 
short hairpin RNAs (shRNAs) to knock down (KD) Csde1 in mouse 
primary cultures of cortical neurons. Endogenous Csde1 expression 
was markedly reduced after transfection of neurons with these two 
shRNAs (fig. S5). Transferring the shRNAs at day 0 in vitro (DIV0) 
and analyzing neurites at day 5 (DIV5), we observed a marked in-
crease in both the total neurite length and axonal length in Csde1 
KD neurons (Fig. 3A). In addition, we observed reduced dendritic 
complexity in the Csde1 KD neurons at DIV14 (Fig. 3B). To examine 
the role of Csde1 on dendritic spine development and morphogenesis, 
we examined the secondary dendrites of Csde1 KD neurons at 
DIV18 and observed that Csde1 KD neurons generated fewer dendritic 
spines compared with controls (Fig. 3C), consistent with fewer synaptic 
contacts. These differences were accompanied by thin or branched 
spines, consistent with an immature spine morphology (Fig. 3C). 
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These results suggest that Csde1 is essential for normal develop-
ment of axons and dendritic spines.
We also performed immunostaining using antibodies to synaptic 
markers vGlut (excitatory) and vGAT (inhibitory). We found that 
the numbers of both excitatory and inhibitory synapses were markedly 
reduced in Csde1 KD neurons compared with controls (Fig. 3D). 
Coexpression of human CSDE1 (hCSDE1) rescued axonal, dendritic, 
and synaptic phenotypes (Fig. 3, A to D). Last, we performed whole-
cell electrophysiology from neurons transfected with either control 
or shRNA to examine whether Csde1 KD affects excitatory and 
Table 2. Genotype-phenotype correlations of 17 probands with CSDE1 LGD variants. +, present; −, absent; blank, not reported. DN, de novo; MI, maternal 
inheritance; PI, paternal inheritance; NMI, not maternal inheritance; EEG, electroencephalographic. 
Patient ID
PU2.
p1
BU2.
p1
NN1.
p1
SS1.
p1
SU2.
p1
AA.
p1
TI.
p1
BU1.
p1
CC1.
p1
CC4.
p1
PU1.
p1
CC2.
p1
CC3.
p1
TA.
p1
SU1.
p1
TU.
p1
SS2.p1 Total
Variant inheritance PI PI DN DN DN MI DN DN DN PI MI DN DN PI PI NMI MI 8 DN,8 INH
Age at last 
examination (years)
4.5 3.5 12 17 7 19 11 13 8 5 8.4 3 3.8 7.9 5.2 5.9 10 3–19
Sex F M M F F M M F M M F M M M M M F 11 M, 6 F
Neurodevelopmental problems
 Developmental 
delay (speech)
+ + + + + + + + + + + + + + + + + 17/17
 Developmental 
delay (motor)
+ + − + + + + + + + + + + + + + − 15/17
 ASD/autistic 
features*
− + + + − − ± + + + + + + − + 11/15
 ID† + + + + ± + + + + + + ± + + + + ± 14/16
Neurological problems
 Epilepsy/seizure‡ − − − − − ± + ± ± + + ± − − − − 7/16
 EEG abnormalities + − + − + + − − + + − − 6/12
 MRI brain 
abnormalities
+ + − − + − + + − + − − − + 7/14
 Macrocephaly + + − + − + − − − − + − + − − 6/14
 Sleep 
disturbances
− − + + − − − − + − − − − + 4/14
Behavior problems
 Repetitive 
behavior
+ + + + − + + + + + + + + + − + 14/15
 ADHD + − + + − − + + + + + − + 9/13
 Anxiety + + − + + − + − + + − − − 7/13
 Obsessive 
behavior
− + − − − + + − + − − − − 4/13
 Self-injurious 
behavior
− − − − − + + − + − − − 3/12
 Aggressive 
behavior
− − − − − − + + − − − − − − 2/14
Systemic problems
 Eye 
abnormalities§
+ + + − + + + − + − − − − 7/13
 Recurrent 
infections
− − − + − − − + + + + + − 6/13
 Hypotonia + + − + − − + + − + − − − 6/13
 Hand deformity║ + + + + − − − − − − + − − + − 6/15
 Short stature + + − − + − − − − − − − − − − − 3/16
*+, ASD; ±, autistic features.   †+, mild to severe ID; ±, below average or learning disability.   ‡+, epilepsy; ±, seizure but no epilepsy diagnosis.   §Eye 
abnormalities are variable (see table S1).   ║Hand deformity including brachydactyly (4), polydactyly (1), and clinodactyly (1).
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inhibitory neurotransmission. Both the frequency and amplitude of 
miniature excitatory postsynaptic currents (mEPSCs) and miniature 
inhibitory postsynaptic currents (mIPSCs) were significantly de-
creased in Csde1 KD neurons (Fig. 3, E and F) when compared to 
controls. Again, coexpression of hCSDE1 rescued the abnormal 
neurotransmission phenotypes (Fig. 3, E and F).
Our HITS-CLIP and RIP-seq experiments identified Ctnnb1 mRNA 
as a binding target of Csde1 (table S2). -Catenin, encoded by Ctnnb1, 
is the key downstream component of the canonical Wnt signaling 
pathway and is critical for neuronal dendritic morphogenesis (24). 
To investigate the potential molecular mechanisms underlying the 
deficient dendritic spine phenotypes observed in Csde1 KD neurons, 
we assayed -catenin mRNA and protein expression level in Csde1 
KD neurons. Immunoblot experiments showed that -catenin protein 
expression was markedly reduced in Csde1 KD neurons (Fig. 3G), 
although mRNA expression levels were not significantly altered. 
These data are consistent with previous reports that Csde1 regulates 
expression at the posttranscriptional level (25). We then expressed 
a degradation-resistant -catenin mutant construct alongside Csde1 
KD in mouse cortical neurons. Expression of stabilized -catenin 
rescued the abnormal spine density and morphology and neuro-
transmission defects associated with Csde1 disruption (Fig. 3, B to F). 
To determine whether dendritic spine and synapse phenotypes 
arise from decreased Wnt/-catenin signaling efficiency in Csde1 
KD neurons, we sought to rescue neurodevelopmental phenotypes 
by stimulating the pathway upstream of the putative pathway block. 
As anticipated, treatment with the upstream ligand lithium rescued 
the abnormal spine density and morphology and neurotransmission 
(Fig. 3, C and D).
Together, these results indicate that Csde1 is essential for proper 
neuronal and synapse development. Specifically, disruption of Csde1 
causes neurite overgrowth, abnormal dendritic spine morphology, 
impaired synaptogenesis, and impaired neurotransmission in mouse 
primary cultures of cortical neurons. Csde1 disruption suppresses 
Ctnnb1 expression, which, in turn, contributes to abnormal dendritic 
spine morphogenesis and synapse development.
Disruption of Csde1 interferes with synapse growth 
and neurotransmission in vivo
The Drosophila neuromuscular junction (NMJ) provides a valuable 
tool for studying genes associated with NDDs. A homolog of human 
CSDE1 (hCSDE1), named Drosophila Upstream of N-ras (dUnr), is 
highly conserved at the protein level, sharing most functional domains 
with hCSDE1 (22, 25). We collected and tested several fly strains 
relating to dUnr, including a hypomorphic mutant (dunr) and two de-
ficiency strains that removed dUnr (Df1 and Df2) (fig. S6). NMJ 
morphological analysis at muscle 4 was performed on the wild-type 
(WT) and dUnr strains by dissecting third-instar wandering larvae 
and labeling NMJs with anti–horseradish peroxidase (HRP) antibody 
and anti-discs large (DLG) antibodies, which mark the neuronal 
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Fig. 2. Enrichment analyses of Csde1 RNA binding targets. (A) Bar plot shows Csde1-binding targets significantly enriched in seven ASD-related gene sets, especially 
the FMRP RNA binding targets. (B) Venn diagram shows the overlap of the RNA binding targets of CSDE1 and other ASD-associated RBPs (FMRP and RBFOX). (C) Venn 
diagram shows the overlap of the SFARI genes that are RNA binding targets of CSDE1, FMRP, and RBFOX, with gene names indicated. (D) Bar plot shows Csde1-binding 
targets enriched in neuronal development– and synapse development–related cell components [Fisher’s exact test, false discovery rate (FDR)–corrected]. Top 15 signifi-
cant cell components are shown.
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Fig. 3. Disruption of Csde1 interferes with neuronal development. (A) Csde1 KD promoted neurite and axon growth (NC, 73 neurons; Csde1 KD1, 60 neurons; Csde1 KD2, 
53 neurons; Csde1 KD1 + WT, 82 neurons). Neurons were colabeled with 4′,6-diamidino-2-phenylindole (DAPI) (nuclei), green fluorescent protein (GFP) (overall neuronal 
morphology), and SMI 312 (axon). Scale bar, 100 m. (B) Csde1 KD reduced the complexity of dendritic arborization (NC, 32 neurons; Csde1 KD1, 21 neurons; Csde1 KD2, 
42 neurons; Csde1 KD2 + WT, 27 neurons; Csde1 KD2 + Ctnnb1, 26 neurons). (C) Csde1 KD disrupted dendritic spine morphogenesis and maturation (NC, 27 neurons; 
Csde1 KD1, 41 neurons; Csde1 KD2, 23 neurons; Csde1 KD2 + WT, 40 neurons; Csde1 KD2 + Ctnnb1, 28 neurons; Csde1 KD2 + Licl, 23 neurons). Scale bar, 10 m. (D) Csde1 KD 
reduced the number of excitatory (vGlut) and inhibitory (vGAT) synapses (NC, 41 neurons; Csde1 KD2, 46 neurons; Csde1 KD2 + WT, 30 neurons; Csde1 KD2 + Ctnnb1, 39 neurons; 
Csde1 KD2 + Licl, 28 neurons). Scale bar, 10 m. (E and F) Voltage-clamp whole-cell recordings showed that both frequency and amplitude of mEPSCs and mIPSCs were 
decreased in Csde1 KD neurons (three neurons for each condition). (G) Immunoblot showed that -catenin expression was markedly decreased in Csde1 KD neurons. 
Statistical data were presented as means ± SEM. *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001.
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membranes and the postsynaptic membranes of type Ib boutons, 
respectively. We observed a significant increase of both total bouton 
number and satellite bouton number in dUnr homozygote mutants 
(dunr) (Fig. 4A), with heterozygous mutants (dunr/+) showing a more 
modest but significant increase. Two lines of dUnr hemizygous 
mutants, dunr/Df1 and dunr/Df2, demonstrated identical synaptic 
overgrowth phenotypes, thereby minimizing effects of genetic back-
ground (Fig. 4A).
To clarify whether disruption of dUnr in the nervous system 
contributes to the defects of NMJs, we established a dUnr KD line 
using UAS-dUnr-RNAi constructs (fig. S6) driven by pan-neuronal 
Elav-Gal4. Neuronal KD of dUnr mimicked dUnr mutant pheno-
types, resulting in a significant increase in both total and satellite 
bouton numbers (Fig. 4B). To eliminate the possibility of off-target 
effects from the KD line, we coexpressed an RNA interference 
(RNAi)–resistant dUnr (dUnr-res), which rescued the phenotypes 
(Fig. 4B). Synaptic overgrowth induced by neuronal KD can be sup-
pressed by coexpression of hCSDE1 (hCSDE1-res) (Fig. 4B), indi-
cating that the function of hCSDE1 and dUnr is conserved during 
synapse development. Considering the intriguing overlap of binding 
targets between Csde1 and FMRP and that overexpression of dFmrp 
in Drosophila has inverse or gain-of-function phenotypes as compared 
with loss of function, we tested whether overexpression of dUnr or 
hCSDE1 also presents inverse phenotypes when compared with loss 
of dUnr. Unfortunately, there is no significant difference for both 
bouton number and satellite bouton number in dUnr or hCSDE1 
overexpression lines driven by pan-neuronal Elav-Gal4 (fig. S7).
To assess the functional consequences of disrupted synapse 
development, we performed electrophysiological analyses of NMJs 
at muscle 6/7 of the third-instar larvae using intracellular recordings 
at 0.6 mM Ca2+. We recorded the evoked excitatory junction potentials 
(EJPs), which reflect the evoked transmitter release, and the miniature 
EJPs (mEJPs), which reflect the spontaneous transmitter release. 
We observed a mild decrease of the EJP amplitudes and mild but 
not significant decrease of mEJP amplitudes in both dunr/Df1 and 
Elav-RNAi lines compared with the controls (Fig. 4C). There was 
no significant alteration of quantal contents in both lines, indicating 
no or very minor effect of dUnr on synaptic efficacy (Fig. 4C). 
Although the mEJP amplitude was not significantly altered, the mEJP 
frequency was markedly decreased in both lines (Fig. 4C), indicating 
impaired synaptic transmission in NMJs. We then performed im-
munostaining for the presynaptic active zone component Bruchpilot 
(BRP) and the postsynaptic glutamate receptor IIA (GluRIIA). We 
observed a slight increase of BRP fluorescent intensity (Fig. 4D) and 
a marked decrease of GluRIIA fluorescent intensity (Fig. 4E). Reduced 
mEJP frequency is often associated with the reduced BRP. However, 
we observed the opposite. Changes in mEJP amplitude are often 
attributable to changes in glutamate receptor. Although we observed 
a marked decrease of GluRIIA intensity, the mEJP amplitude only 
showed very mild decrease. One underlying explanation is that the 
compensatory mechanisms in Drosophila larval NMJs may adjust 
presynaptic and postsynaptic responses to maintain synaptic trans-
mission efficacy, which have been observed in previous studies (26–28). 
These results suggest that loss of dUnr disrupts normal synapse 
development and function.
Considering that abnormal satellite boutons usually reflect defective 
synaptic endocytosis, we asked whether disruption of CSDE1 causes 
abnormal synapse endocytosis. We labeled the synaptic vesicle with 
FM 1-43 dye, which can be taken up in a synaptic vesicle by endo-
cytosis, in dunr/Df1 and the KD lines. We observed a significant reduced 
amount of loaded FM 1-43 dye in both dunr/Df1 and the KD lines 
(Fig. 4F), indicating a potential role of dUnr in synaptic endocytosis.
DISCUSSION
We report a significant association of both de novo and inherited 
truncating variants in CSDE1 among pediatric patients with autism 
and more broadly defined NDDs. In total, we present detailed clinical 
and genetic information for 17 patients and observe several consistent 
phenotypes, including ASD, mild-to-severe ID, and speech and motor 
developmental delay. In addition, seizures, macrocephaly, anxiety, 
ADHD, hypotonia, and ocular defects were also associated with 
CSDE1 LGD variants. The common phenotypes observed in the 
probands suggest a new ASD-related syndrome defined by CSDE1 
LGD variants.
Although LGD variants are nearly absent from population controls, 
it is interesting that in half the cohort, CSDE1 truncating variants are 
inherited from a parent. Although learning disabilities, delayed develop-
ment, and reduced cognitive ability were noted in some of the carrier 
parents, transmitting parents generally presented with less severe 
phenotypes than the affected children. Similarly, our single adult 
patient was higher functioning but did experience psychiatric issues 
later in life, including a diagnosis of schizophrenia. The basis for 
this phenotypic variability is unknown and may reflect modifying 
genetic factors or, alternatively, the condition may change over time, 
improving in certain facets and worsening with others at different 
neurodevelopmental stages throughout life. Longitudinal studies of 
CSDE1 families, including more detailed phenotypic and genetic 
assessment of carriers, are needed to better understand the progression 
and risk factors associated with variable expression of this disorder 
across individuals and age.
It is well known that variants in two RBP-encoded genes, FMR1 
and RBFOX1, cause ASD and other NDDs (29, 30). Our study presents 
a new highly constrained RBP gene, CSDE1, causing a new ASD-related 
syndrome. RBP targets are important predictors of disease pathology, 
and the targets of both FMRP and RBFOX have already been well 
established (10, 11). In this study, we focused on identifying the targets 
of Csde1 binding in the mouse brain and found a large overlap with 
those of FMRP and RBFOX. Similarly, we find that Csde1-binding 
targets are significantly enriched in ASD-associated genes, including 
dozens of high-risk ASD genes, such as GRIN2B, STXBP1, GRIA1, 
CTNNB1, SNAP25, and TCF4, as well as synapse development and 
plasticity-related cell components or pathways. It should be noted 
that several well-defined ASD genes, which did not make our high- 
confidence set based on overlap between independent experiments, 
were also validated as Csde1-binding targets, including SYNGAP1, 
DYRK1A, TNRC6B, and NCKAP1. Therefore, it is critical to design 
additional more stringent studies to further delineate the full spectrum 
of Csde1 targets.
RBPs regulate almost all steps of RNA expression, including tran-
scription, alternative splicing, and translation (31). Although there 
is an intriguing overlap of CSDE1 and FMRP targets, based on the 
current knowledge, the underlying regulation mechanisms of CSDE1 
and FMRP appear to differ. First, CSDE1 regulates mRNA stability 
and/or translation by interacting with distinct complexes mainly in 
the cytoplasm (22). A paradigmatic case is the regulation of internal 
ribosome entry site–mediated translation (32). In comparison, FMRP 
is associated with suppressed messenger ribonucleoprotein particles 
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Fig. 4. Disruption of dUnr interferes with synapse development and transmission in Drosophila. (A) Left: Representative NMJ4 synapses of dUnr-related lines 
(WT, dunr/+, dunr, dunr/Df1, and dunr/Df2). Right: Both bouton number and satellite bouton number were increased in dunr/+ line (n = 22), dunr line (n = 58), dunr/Df1 line 
(n = 23), and dunr/Df2 line (n = 25) compared to control (n = 61). The boutons were costained with anti-HRP labeling the neuronal plasma membrane (red) and anti-DLG 
(green) labeling a postsynaptic scaffold protein. Magnified image of the boxed region at left bottom shows the terminal bouton or the satellite bouton. Scale bar, 5 m. 
(B) Left: Representative NMJ4 morphology of the Elav/+ line, a pan-neuronal dUnr KD line (Elav-RNAi), a Drosophila UNR rescue line (dUnr-res), and a human CSDE1 rescue 
line (hCSDE1-res). Right: Both bouton number and satellite bouton number were increased in Elav-RNAi line (n = 45) compared to Elav/+ line (n = 45). In dUnr-res line (n = 34) 
and hCSDE1-res line (n = 28), the numbers were decreased compared to Elav-RNAi line (n = 45). Scale bar, 5 m. (C) Left: Representative traces of EJPs and mEJPs in 
the indicated genotypes. Right: The amplitudes of EJPs were mildly decreased in both dunr/Df1 line (WT: n = 9; dunr/Df1: n = 13) and pan-neuron KD line (Elav/+: n = 29; 
Elav-RNAi: n = 17). Slightly but not significantly decreased mEJP amplitude and no significant change of quantal content were observed on both KD and dunr/Df1 lines. NS, not 
significant. (D) The normalized fluorescent intensity of BRP was slightly increased in dunr (n = 76) and dunr/Df1 (n = 63) lines compared to controls. Scale bar, 5 m. (E) The 
normalized fluorescent intensity of postsynaptic GluRIIA was markedly reduced in dunr/Df1 (n = 18), dunr/Df2 (n = 23), and KD lines (n = 25) compared to controls. Scale 
bar, 5 m. (F) Decreased normalized fluorescent intensity of FM 1-43 dye was detected in dunr (n = 14), dunr/Df1 (n = 40), and KD (n = 61) lines compared to controls. Scale 
bar, 5 m. Statistical data were presented as means ± SEM. *P < 0.05, **P < 0.01, and ***P < 0.001.
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and actively translating polyribosomes during translation (33, 34) 
and is believed to specifically bind to mRNAs and regulate their 
translation. Second, in many cases, loss of FMRP-mediated regulation 
leads to increased translation and protein levels of the targets. Our 
study shows that loss of Csde1 leads to a suppression of Ctnnb1 
protein levels. Third, from the functional perspective, dendritic spine 
density is increased on cortical neurons in both FXS humans and 
Fmr1 knockout mice (35, 36). Excitatory junction current amplitudes 
were significantly elevated in dFmrp null mutants (37). However, in 
this study, we observed decreased spine density in mouse cortical 
neurons and mildly decreased EJP amplitudes in KD and mutant 
Drosophila. Moreover, overexpression of FMRP leads to inverse or 
gain-of-function phenotypes as compared to the loss of FMRP in 
many instances. In this study, we did not observe synapse overgrowth 
in the CSDE1 overexpression line when compared to KD or mutant 
lines, where both bouton number and satellite bouton number de-
creased. One possibility may be an antagonistic functional relationship 
between CSDE1 and FMRP, although further functional studies will 
be required to test this hypothesis.
Several studies have recently reported that disruption of CSDE1 
leads to defects in normal neural development at a variety of levels. 
Kobayashi and colleagues, for example, found Csde1 expressed in 
migrating precerebellar neurons, and shRNA-mediated inhibition 
resulted in a failure of precerebellar neurons to complete migration 
to their prospective target regions. This suggested a crucial role for 
Csde1 in the proper control of both radial and tangential migration 
of precerebellar neurons (12). Another recent study reported that 
CSDE1 is highly expressed in human embryonic stem cells (hESCs), 
where it serves to maintain their undifferentiated state, preventing 
a default neural differentiated state. It was suggested that CSDE1 
serves as a central posttranscriptional regulator of hESC identity 
and neurogenesis (13).
In the current study, we observed abnormal spine development 
in Csde1 KD neurons with an overall decrease in spine density and 
the prevalence of filopodia-like immature spines. Structural changes 
of dendritic spines are correlated with functional changes of neural 
circuitry and synapse plasticity. We found that Csde1 deficiency 
consistently suppresses excitatory and inhibitory synaptic transmission 
in cultured neurons. In the Drosophila model, we found that dis-
ruption of dUnr led to impaired NMJ synapse growth, as indicated 
by increased total synaptic and satellite bouton number. These 
morphological abnormalities were accompanied by defect synapse 
endocytosis and impairment in synaptic function. Presynaptic KD 
of dUnr mimicked these phenotypes, and synaptic overgrowth 
could be suppressed by coexpression of dUnr and hCSDE1. Our 
results argue that dUnr and hCSDE1 play an important role in synapse 
development and function. Specifically, we propose that synaptic 
maturation is dependent on CSDE1 activity, and loss-of-function 
variants of CSDE1 contribute to clinical outcomes via defects in 
synaptic connectivity and transmission.
Our data further suggest that Csde1 positively regulates -catenin 
in mouse cortical neurons at the posttranscriptional level. The binding 
of CSDE1 with -catenin was also reported in a recent study that 
investigated the CSDE1 targets in melanoma cell (38). Depletion of 
CSDE1 in melanoma cells reduced CSDE1 expression at the protein 
level, which is consistent with our results. Moreover, the reduced 
CSDE1 expression resists the presence of proteasome inhibitors, 
suggesting that CSDE1 may regulate -catenin expression at the 
translational level (38). In this study, expression of -catenin or 
activation of the Wnt signaling pathway rescues these Csde1 deficiency 
defects. In addition to -catenin, we also found that Csde1 binds 
another important Wnt signaling pathway–related gene, TCF4, which 
functions as one of the major transcriptional mediators of the canonical 
Wnt signaling pathway. Because -catenin is critical for dendritic 
morphogenesis (24) and defects in Wnt/-catenin signaling have been 
strongly implicated in the development of ASD (39), we hypothesize 
that Csde1 regulates dendritic spine maturation and synapse function, 
in part, through regulation of the Wnt/-catenin signaling pathway.
In summary, through international collaboration and targeted 
sequencing of large patient cohorts, we identified an excess of LGD 
variants in a highly conserved RBP-encoded gene, CSDE1, and de-
fined a new ASD-related syndrome. Although little is known to date 
about the function of CSDE1 in neurodevelopment, our HITS-CLIP 
and in vitro and in vivo functional analyses indicate that CSDE1 plays 
an essential role in neuronal and synapse development, including 
synapse transmission. The significant overlap of RNA binding targets 
between CSDE1 and FMRP suggests that behavioral and potential 
therapeutic interventions (40) for FXS are also likely to benefit patients 
with CSDE1-related syndrome.
MATERIALS AND METHODS
Study cohorts and targeted sequencing
We initially targeted 4045 ASD probands from the Chinese population 
[ACGC cohort described previously (41)] for CSDE1 sequencing. 
ACGC patients were diagnosed primarily according to DSM-4 and/
or DSM-5 criteria, documenting additional comorbid conditions where 
possible. Peripheral blood DNA from all patients with ASD and their 
parents, where available, was collected after obtaining informed con-
sent. Genomic DNA was extracted from whole blood using a standard 
proteinase K digestion and phenol-chloroform method. In the second 
stage, targeted sequencing was performed on a larger international 
cohort [described elsewhere (42)] with 10,745 patients with a primary 
diagnosis of ASD and/or ID/DD. Informed consents from all partici-
pants were obtained. This study was approved by the Institutional 
Review Board (IRB) of Central South University.
Targeted sequencing of CSDE1 was performed using smMIP 
technology—a highly cost-effective targeted sequencing method (15). 
In brief, MIPs were designed using MIPgen with an updated scoring 
algorithm. Amplification of the captured DNA was performed as 
previously reported (41). Libraries were sequenced using the Illumina 
HiSeq 2000 platform. Clean reads were aligned against hg19 
(GRCh37 reference genome) with BWA-MEM (v0.7.13) (43) after 
removing incorrect read pairs and low-quality reads. Single-nucleotide 
variants and indels were called with FreeBayes (v0.9.14) (44). Variants 
exceeding 10-fold sequence coverage and read quality more than 20 
(QUAL > 20) were annotated with SeattleSeq (45) Annotation 138 
using reference GRCh37/hg19. LGD variants and rare missense 
variants in CSDE1 (minor allele frequency < 1% in ExAC) were selected 
for validation using Sanger sequencing in both patients and parents 
where available.
Statistical analyses for CSDE1 LGD variants
De novo significance was calculated using a binomial model that 
incorporates gene-specific variant rates estimated from an overall 
rate of variation in coding sequences and estimates the relative locus- 
specific rates based on the CH model (15) with an expected rate of 
1.5 de novo variants per exome. P values were corrected genome-wide 
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for the number of genes (18,946). Burden of CSDE1 LGD variants 
between patients and ExAC nonpsychiatric samples was performed 
using Fisher’s exact test. All statistical analyses were performed us-
ing the R statistical language (v3.2.4) (www.r-project.org/).
HITS-CLIP experiments using mouse brain
Two independent Csde1 HITS-CLIP experiments were performed 
with the mixture of three whole-brain tissue lysates of 15-day-old 
(P15) mice using the standard protocols. Tissues were triple washed 
with ice-cold phosphate-buffered saline (PBS), and ultraviolet (UV) 
cross-linking was performed with UV irradiation type C (254 nm) 
at 400 mJ/cm2. Samples were ground, and cell lysis was performed 
in cold lysis buffer (1× PBS, 0.1% SDS, 0.5% NP-40, and 0.5% sodium 
deoxycholate) supplemented with a 1% ribonuclease inhibitor (Takara, 
Kusatsu, Shiga, Japan) and 2% protease inhibitor cocktail (Roche, 
Basel, Switzerland) for 30 min. Cell lysates were cleared by centrifu-
gation at 10,000 rpm for 10 min at 4°C, and the supernatants were 
used for immunoprecipitation. Study protocols comply with all rel-
evant ethical regulations and were approved by the IRB of Central South 
University. All animal experiments were approved by the Institutional 
Animal Care and Use Committee of the Central South University.
For DNA digestion, RQ1 (Promega, Madison, WI; final concen-
tration, 0.05 U/l) was added to the lysate and incubated at 37°C for 
3 min. RNA digestion was performed by adding micrococcal nuclease 
(1:10,000, Thermo Fisher Scientific, Waltham, MA), followed by 
incubation at 37°C for 10 min. For immunoprecipitation, 600 l of 
lysate was incubated with 15 g of antibody or control immuno-
globulin G (IgG) antibody overnight at 4°C. The immunoprecipitates 
were further incubated with protein A/G Dynabeads for 2 to 3 hours 
at 4°C. After applying to a magnet and removing the supernatants, 
the beads were sequentially washed with wash buffer (1× PBS, 1% SDS, 
0.5% NP-40, and 5% sodium deoxycholate), high-salt wash buffer 
(5× PBS, 1% SDS, 0.5% NP-40, and 5% sodium deoxycholate), and PNK 
(polynucleotide kinase) buffer [50 mM tris (pH 7.4), 10 mM MgCl2, 
and 0.5% NP-40] twice.
After washing with PNK buffer as described above, dephosphoryl-
ation and phosphorylation were performed with FastAP thermo-
sensitive alkaline phosphatase (Thermo Fisher Scientific, Waltham, MA) 
and T4 polynucleotide kinase (Thermo Fisher Scientific, Waltham, MA). 
The immunoprecipitated protein-RNA complex was eluted from the 
beads by heat denaturing and resolved on a Novex 4-12% Bis-Tris 
precast polyacrylamide gel (Invitrogen, Carlsbad, CA). The protein- 
RNA complexes were cut from the gel (Invitrogen, Carlsbad, CA), 
and RNA was extracted with TRIzol after digesting the proteins. The 
recovered RNA was used to generate libraries with a TruSeq small 
RNA library preparation kit (Gnomegen, San Diego, CA) following 
the manufacturer’s instructions. Libraries corresponding to 150 to 
250 base pairs (bp) were purified and quantified. The libraries were 
sequenced on the Illumina NextSeq 500 system with 151-bp paired-
end reads by ABlife Inc. (Wuhan, China).
HITS-CLIP data analyses
Raw reads were first discarded if containing more than 2-N bases, 
then reads were processed by clipping adaptor and removing low- 
quality bases, and too short reads (less than 13 nucleotides) were 
also dropped. FASTX-Toolkit (version 0.0.13) was used to obtain a 
clean set of reads. Clean reads were mapped to the GRCm38.p3 version 
of the mouse genome by TopHat2 (46). After removing duplicate 
reads, the remainder was used for subsequent analyses.
CLIP sequencing peak calling
Two software programs, Piranha and Ablife, were used to perform 
peak calling. Piranha has been described elsewhere (47). The Ablife 
analyses are summarized as follows. After alignment, identical 
aligned reads were counted and merged as unique reads. We identified 
clusters based on overlap between alignment genome coordinates. 
To select the confident binding sites from the background, we use 
the “in silico random IP” strategy (48). The entire process was re-
peated 500 times, and false discovery rate (FDR) (P value) was de-
termined by counting the observed number of maximum clusters 
from each of 500 repeats. All observed peaks were assigned an FDR 
value according to peak height, and peaks with FDR no greater than 
0.01 were chosen as a confident binding peak.
RNA immunoprecipitation–quantitative polymerase  
chain reaction
TRIzol (Invitrogen, Carlsbad, CA) was used to extract total RNAs 
from the immunoprecipitate of Csde1 according to the manufacturer’s 
instructions. Random primers were then used for complementary 
DNA (cDNA) synthesis. To detect whether Csde1 target genes were 
significantly and specifically enriched in the Csde1 immunoprecipitate, 
we used IgG RNA as a reference and performed quantitative reverse 
transcription polymerase chain reaction (RT-PCR) to determine the 
relative level of specific RNAs in the IgG and Csde1 immunoprecipitates. 
Quantitative PCR (qPCR) data represent the mean values from at 
least three independent experiments. Various genes were selected 
for PCR amplification in both Csde1 and IgG immunoprecipitates.
Enrichment analyses for Csde1 RNA binding targets
Gene Ontology and KEGG pathway analyses were performed using 
the online tool DAVID (http://david.abcc.ncifcrf.gov/). Multiple testing 
comparisons were performed using the Benjamini-Hochberg FDR 
method. Enrichment of Csde1-binding targets in ASD-related gene 
sets was performed using Fisher’s exact test using all protein-coding 
genes expressed in the mouse brain as the background (49).
Plasmids and antibodies for mouse primary neuron analyses
The full-length CSDE1 open reading frame (NM_001242891) was 
purchased from GeneCopoeia (San Diego, CA). CSDE1 was then 
cloned into a pCAGGS–IRES–green fluorescent protein (GFP) vector 
by site-directed mutagenesis (Asc I and Xho I) using the following 
primers: 5′-TTGGCGCGCCATGGAGAACGTTTTTACT-3′ 
(forward) and 5′-CCGCTCGAGTTAAGCGTAGTCTGGGAC-
GTCGTATGGGTAGTCAATGACACCAGC-3′ (reverse). The mouse 
Csde1 shRNAs were cloned in the pFUGW-H1-GFP vector between the 
Xba I and Bam HI restriction sites (shRNA1 target: 5′-GCTCTCTG-
CCCAAAGAAATCA-3′; shRNA2 target: 5′-GCATTACTGAG-
GAAGCTAATC-3′; NC target: 5′-CCAGATCAGGTGGCAATAAT-3′). 
The stabilized form of -catenin construct was from Yu and Malenka 
(24). Lentivirus was provided by Obio Technology (Shanghai, China). 
The antibodies used in this study included the following: rabbit anti- 
CSDE1 (1:1000; Abcam, Cambridge, MA; ab113207), rabbit anti- 
CSDE1 (1:2000; Sigma-Aldrich, St. Louis, MO; HPA018846), mouse 
anti–SMI 312 (1:500; BioLegend, San Diego, CA; 837904), mouse anti– 
-catenin (1:2000; Cell Signaling Technology, Danvers, MA; 2698), rabbit 
anti-GluR1 (1:1000; Cell Signaling Technology, Danvers, MA; 13185), 
mouse anti-GAPDH (glyceraldehyde-3-phosphate dehydrogenase) 
(1:5000; Abcam, Cambridge, MA; ab9484), guinea pig anti-vGlut 
(1:2000; Millipore, Hessen, Germany; AB5905), rabbit anti-vGAT 
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(1:500; SYSY, Goettingen, Germany; 131002), rabbit anti–-tubulin (1:5000; 
Cell Signaling Technology, Danvers, MA; 2148), rabbit anti-GFP 
(1:500; Invitrogen, Carlsbad, CA; A-11122), and rabbit anti–-tubulin 
(1:5000; Sigma, St. Louis, MO; T2200). Appropriate secondary antibodies 
conjugated with Alexa Fluor dyes anti-mouse or rabbit or guinea pig 
(1:500 for immunofluorescence and 1:10,000 for Western blot; 
Jackson ImmunoResearch) were used to detect primary antibodies.
Mouse primary neuron culture
Embryonic day 15 (E15)–E16 mouse cortical neurons were dissected 
and plated at a density of 5 × 104 to 20 × 104 cells per well onto cover-
slips coated with or without poly-d-lysine (0.1 mg/ml; BD Biosciences, 
San Jose, CA) in plating medium [minimum essential medium 
(MEM) + 10% fetal bovine serum (FBS); Gibco, Carlsbad, CA]. 
After 3 to 4 hours, medium was changed to culturing medium 
(Neurobasal medium + B27 + GlutaMAX; Invitrogen, Carlsbad, CA). 
Cells were transfected via electroporation with an Amaxa Nucleofector 
apparatus (Amaxa, Cologne, Germany) at 0 days in vitro (DIV0) 
according to the manufacturer’s instructions. After DIV5, the cells 
were fixed for neutric length analyses. For qPCR or Western blot 
analyses, neurons were infected 2 or 6 days after plating (DIV2 or 
DIV6) with indicated lentiviruses at a multiplicity of infection of 2, 
and cells were harvested at DIV6 or DIV15. For dendritic length 
analyses, neurons were transfected by calcium phosphate transfec-
tion at DIV5 and fixed at DIV15 for further analyses. For rescue 
experiments, we cotransfected each group with three plasmids 
using a 1:1:0.5 ratio of WT CSDE1 or CTNNB1, shRNAs, and en-
hanced GFP. For experiments examining the effect of Wnt/-catenin 
pathway activation on neurodevelopment in culture, neurons were 
treated with 5 mM lithium (Sigma, St. Louis, MO) for 7 days. Study 
protocols complied with all relevant ethical regulations and were 
approved by the IRB of Central South University.
Mouse primary neuron RNA extraction and real-time PCR
Total RNA was extracted from cell lysates using TRIzol Reagent 
(Invitrogen, Carlsbad, CA), and 1 g was retrotranscribed using the 
ThermoScript RT-PCR System (Invitrogen, Carlsbad, CA). Real-time 
PCRs were performed in triplicate on an Applied Biosystems 7900HT 
Fast Real-Time PCR system using 10 ng of cDNA, 5 l of SYBR Green PCR 
Master Mix (Applied Biosystems, Foster City, CA), and 150 nM specific 
primers (sequences available on request) in a final volume of 10 l.
Csde1 immunoblotting
As Csde1 is abundantly expressed in the mouse cortex, cortical tissue 
homogenates were prepared from mouse brains at different devel-
opmental stages. Protein extract of mouse cortical tissue and primary 
neuronal culture were immersed in radioimmunoprecipitation assay 
buffer supplemented with a cOmplete protease inhibitor cocktail tablet 
(Roche, Basel, Switzerland) and sonicated, denatured in 2× SDS loading 
buffer with 4% -mercaptoethanol for 10 min at 95°C, and then sep-
arated by 12% SDS–polyacrylamide gel electrophoresis. The protein 
on the gel was transferred to a polyvinylidene fluoride membrane 
(Immobilon-P; Millipore, Hessen, Germany), and membranes were 
blocked with 5% nonfat milk in 1× PBST for 1 hour. The mem-
branes were then incubated in primary antibodies overnight at 4°C, 
washed three times in 1× PBST, and incubated in secondary anti-
bodies for 1 hour at room temperature. The signals were revealed 
by HRP reaction using SuperSignal Chemiluminescent Substrate 
(Thermo Fisher Scientific, Waltham, MA).
Mouse primary neuron immunofluorescence
Cells were washed with 1× PBS three times, fixed in 4% paraformaldehyde 
(PFA) for 15 min, and blocked in 1× PBS buffer with 5% bovine 
serum albumin and 0.1% Triton X-100 (PBST) for 30 min at room 
temperature. The cells were incubated with primary antibodies over-
night at 4°C, washed three times in 1× PBS, and then incubated with 
secondary antibodies at room temperature for 60 min. The signals 
were observed via fluorescence microscopy.
Mouse primary neuron phenotype analyses
Images were obtained using a Leica DM5000B fluorescence micro-
scope equipped with a 10× lens (for neurite development in cultured 
mouse cortical neurons) and a TCS-SP5-II confocal microscope 
equipped with a 20× objective lens (for dendritic development). To 
evaluate neurite development in cultured primary cortical neurons, 
GFP+ cells were randomly selected from each condition, and total 
neurite length was traced with the ImageJ (v1.51j8) software.
For analyses of dendritic development, three-dimensional (3D) 
reconstructions of entire dendritic processes of each GFP+ neuron 
were obtained from Z-series stacks of confocal images. The 2D pro-
jection images were traced with ImageJ. The dendrite complexity was 
analyzed by Sholl analyses. Sholl analysis parameters were as follows: 
starting radius, 10 m; ending radius, 120 m; step size, 10 m. For 
the Sholl analysis, concentric circles with an increasing radius (10 m) 
were placed around the cell body. The number of intersections of 
the dendrites and the concentric circles per radial distance from the 
soma were quantified. Briefly, 8-bit images of cultured neurons 
were traced using the NeuronJ plugin for ImageJ, and tracing files 
(*.ndf files) were generated.
Spine density was measured from secondary branches, from the 
branch point, ranging from 15 to 25 mm in length. The average 
spine density of specific neurons was analyzed statistically and cal-
culated as the total number of spines per 10 m of dendritic length 
of each neuron. The number of synapses was assessed by immunos-
taining samples with antibodies to excitatory (vGlut) and inhibitory 
(vGAT) synaptic markers and counting vGlut (or vGAT) and GFP 
colocalized puncta on dendrites transfected with plasmids. After 
background subtraction, the threshold value for each channel was 
automatically adjusted, following an algorithm previously described. 
The colocalized voxels representing synapses were reported as the 
number of vGlut (or vGAT) and GFP+ puncta per 1 m. Spine density 
was measured in Fiji software (ImageJ v1.47b).
Statistics were performed using GraphPad Prism 5.0 software. 
Compiled data are expressed as means ± SEM. Sample size was 
not predetermined, but numbers of samples are consistent with 
previous publications. One- and two-way analysis of variance 
(ANOVA) followed by either Dunnett’s multiple comparisons test 
(when comparing to control conditions) or Bonferroni multiple 
comparisons test was used for experiments with three or more 
datasets. Equal variances between groups and normal distributions 
of data were presumed but not formally tested. Molecular and 
biochemical analyses were performed using a minimum of three 
biological replicates per condition. P < 0.05 was considered statis-
tically significant.
Whole-cell electrophysiology and data analyses
Voltage-clamp whole-cell recordings were obtained from cultured 
neurons at room temperature (22° to 25°C). An external solution 
containing 126 mM NaCl, 2.5 mM KCl, 1.25 mM NaH2PO4·H2O, 
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26 mM NaCO3, 25 mM glucose, 2 mM MgSO4, and 2 mM CaCl2 
(pH adjusted to 7.2 with KOH) was used for the recordings. For 
recording mEPSCs, glass pipettes with a resistance of 5 to 8 megohms 
were filled with an internal solution consisting of 120 mM CsMeSO3, 
15 mM CsCl, 8 mM NaCl, 0.2 mM EGTA, 10 mM Hepes, 2 mM 
Mg–adenosine triphosphate (ATP), 0.3 mM Na–guanosine tri-
phosphate, 10 mM tetraethylammonium, and 5 mM QX-314 
[5-N-(2,6-dimethylphenylcarbamoylmethyl) triethylammonium 
bromide] (290 to 300 mOsm). pH was adjusted to 7.3 with CsOH. 
Neurons were held at a holding potential of −70 mV. In addition, 
1 M tetrodotoxin and 10 M bicuculline were added to the external 
recording solution. For recording mIPSCs, glass pipettes were filled 
with an internal solution consisting of 140 mM CsCl, 0.1 mM GaCl2, 
2 mM MgCl2, 10 mM Hepes, 0.5 mM EGTA, 4 mM K-ATP, and 
5 mM QX-314 (390 to 300 mOsm). pH was adjusted to 7.3 with 
CsOH. Neurons were held at a holding potential of −70 mV. In ad-
dition, 1 M tetrodotoxin, 10 M CNQX, and 50 M D-AP5 were 
added. The signals were filtered at 2.9 kHz and digitized at 10 kHz 
using an EPC-10 amplifier and PatchMaster (v2x53) software 
(HEKA Elektronic Inc., Germany). Recordings with a pipette access 
resistance of <20 megohms and <20% changes for the duration of 
recording were included. The mEPSC and mIPSC recordings were 
analyzed using Clampfit 10.7 software. The frequency and amplitude 
were measured in each group.
Fly stocks and generation of transgenic flies
All stocks were cultured in standard medium at 25°C. The w1118 
strain was used as the WT control in this study. The Drosophila Unr 
hypomorphic mutant line w1118; PBac{PB}Unrc01923 (FlyBase ID: 
FBst0010757) was previously mapped and tested (50) and was used 
as a mutant (dunr) line in this study. The deficiency strains that re-
moved Unr, Df(3L)BSC815 (abbreviated as Df1) and Df(3L)BSC157 
(abbreviated as Df2), were obtained from the Bloomington Stock 
Center (catalog nos. 27576 and 9544, respectively). UAS-dUnr-RNAi 
was obtained from Tsinghua Fly Center with the genotype y1sc*v1; 
P{TRiP.HMS00494}attP2/TM3, Sb1 (catalog no. THU0937). The 
whole body–expressed Da-Gal4 and pan-neuron–expressed Elav-Gal4 
were supplied by Z. Zhang (Center South University, Changsha, 
Hunan Province, China). Western blotting with rabbit anti-dUnr 
antibodies was performed to identify the expression level of dUnr in 
dunr, dunr/Df1, dunr/Df2, and Da-RNAi lines by extracting protein 
from the whole body of the 4-day-old male flies. Antibody to dUnr 
was provided from Fatima Gebauer Lab (Centre de Regulacio Ge-
nomica, 08003 Barcelona, Spain) (51) and used at a dilution of 1:500. 
Anti–-actin (A2228, Sigma-Aldrich; 1:5000) was used as loading 
control. UAS-dUnr and UAS-hCSDE1 transgenic flies were generated 
by embryo injection into w1118 with a recombinant pUAST vector 
containing the full-length dUnr or hCSDE1 protein-coding sequence, 
respectively. To generate the dUnr-pUAST vector, the coding se-
quence for full-length Drosophila Unr (dUnr, NM_001300054.1) 
was obtained by PCR amplification from cDNA and synonymously 
mutated for resistance to the RNAi fragment of UAS-dUnr-RNAi and 
then subcloned into the pUAST with a Flag tag on the N terminus. The 
full-length human CSDE1 coding sequence (hCSDE1, NM_001242891, 
GeneCopoeia) was subcloned into the pUAST with the same tag. 
Genomic DNA PCR and Western blotting with anti-Flag antibody 
were performed to identify these transgenic lines. Elav-Gal4/+; 
UAS-dUnr/+; UAS-dUnr-RNAi and Elav-Gal4/+; UAS-hCSDE1/+; 
UAS-dUnr-RNAi flies were used as dUnr and hCSDE1 rescue lines. 
Study protocols comply with all relevant ethical regulations and 
were approved by the IRB of Central South University.
Drosophila NMJ bouton number and fluorescence analyses
Whole-mount immunostaining of the Drosophila NMJ was per-
formed essentially as described (52). Briefly, wandering third-instar 
larvae were dissected for body walls in HL3 buffer [70 mM NaCl, 
5 mM KCl, 20 mM MgCl2·6H2O, 10 mM NaHCO3, 115 mM su-
crose, 5 mM trehalose, 5 mM Hepes (pH 7.3)]. After fixing with 
ice methanol for 10 min and washing with 0.2% PBST four times 
for 10 min each, the samples were incubated with primary anti-
body at 4°C overnight, followed by appropriate secondary anti-
bodies for 3 hours at room temperature. The antibodies were diluted 
in blocking agent (0.2% PBST with 5% normal goat serum), and 
these primary and secondary antibodies were used: rabbit anti-HRP 
(1:1000; code number: 323-005-021; Jackson ImmunoResearch, 
West Grove, PA), mouse anti-DLG [4F3; 1:500; Developmental 
Studies Hybridoma Bank (DSHB)], mouse anti-BRP (nc82; 1:25; 
DSHB), mouse anti-GluRIIA (8B4D2; 1:25; DSHB), and Alexa 
Fluor 488– or cy3-conjugated anti-mouse and anti-rabbit secondary 
antibodies (1:500; Jackson ImmunoResearch, West Grove, PA). 
Following the antibody incubation, the samples were washed ex-
tensively and mounted on slides with VectaShield antifade mount-
ing medium (Vector Laboratories, catalog: H-1000) and sealed with 
fingernail polish. Type Ib boutons at muscle 4 of abdominal seg-
ment 3/4 were imaged. Pictures were collected using a Leica TCS 
SP5 confocal microscope. For bouton number analysis, type Ib bou-
ton numbers and satellite bouton numbers were defined as previ-
ously described (53). For fluorescent intensity comparisons, the 
sum of pixel intensity in each channel was recorded by ImageJ 
software (National Institutes of Health), and the anti-HRP stain-
ing was used as control. The ratio of anti-BRP/anti-HRP and anti- 
GluRIIA/anti-HRP staining intensity was calculated for each genotype, 
and different genotypes were normalized to the control in each 
experiment set. Statistical analyses were performed using GraphPad 
Prism 5.0 software (GraphPad Software Inc.). Statistical analysis 
was performed using two-tailed Student’s t tests for comparisons of 
two group means. Data are presented as means ± SEM. A P value of 
<0.05 was considered to be statistically significant. The analyses were 
double blinded.
Drosophila FM1-43 dye labeling
Procedures for the fluorescent dye FM 1-43 assay were described 
previously (54). Wandering third-instar larvae were dissected for 
body walls in modified HL-3 Ca2+-free solution: 70 mM NaCl, 
5 mM KCl, 20 mM MgCl2, 10 mM NaHCO3, 5 mM trehalose, 
115 mM sucrose, and 10 mM Hepes (pH 7.2). For high K+ stimulation, 
the samples were incubated with 4 M FM1-43 dye (Invitrogen, 
F35355) for 5 min in modified HL-3 solution containing 90 mM KCl 
and 1.5 mM CaCl2 [110 mM NaCl, 90 mM KCl, 10 mM MgCl2, 
1.5 mM CaCl2, 30 mM sucrose, 5 mM Hepes, 5 mM trehalose, and 
10 mM NaHCO3 (pH 7.2)] and then washed with modified HL-3 
Ca2+-free solution. The samples were then fixed with 4% PFA for 
35 min and washed three times with PBS before mounting for images. 
Zeiss LSM5 confocal microscope was used to take images with a 
40× objective. Fluorescence intensities were calculated with ImageJ 
software (National Institutes of Health) and normalized to the aver-
age loading fluorescence intensity in controls within the same 
experimental set.
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Drosophila NMJ electrophysiology analyses
Conventional intracellular recordings for assessing NMJ synaptic 
transmissions were carried out as previously described (55). Briefly, 
wandering third-instar larvae were dissected in calcium-free HL3.1 
saline and recorded in HL3.1 saline containing 0.6 mM Ca2+ using 
intracellular microelectrodes (10 to 20 megohms) filled with 3 M KCl. 
Recordings were performed at 20° to 22°C with an Axoclamp 2B 
amplifier (Molecular Devices) in bridge mode, and the recorded 
data were processed with pCLAMP version 10.2 software (Molecular 
Devices). Both EJPs and mEJPs were recorded from muscle 6 of ab-
dominal segment A3. EJPs were evoked by a Grass S48 stimulator 
(Astro-Grass Inc.) with suprathreshold stimulating pulses at 0.3 Hz, 
three EJP responses were collected for each animal, and mEJPs were 
recorded for a period of 60 s after the EJP recording. The data for 
analyses were recorded from cells with resting membrane potentials 
ranging from −60 to −65 mV.
SUPPLEMENTARY MATERIALS
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